Shares of Orchid Pharma today zoomed almost 20 per cent after the company said it has received establishment inspection report (EIR) from the US health regulator for its Alathur facility in Tamil Nadu.
The stock skyrocketed 19.83 per cent to settle at Rs 21.45 -- its highest trading permissible limit for the day -- on BSE.
On NSE, shares of the company soared 19.94 per cent to end at Rs 21.35.
The company has received EIR from the United States Food and Drug Administration (US FDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a BSE filing.
The facility was inspected by the US FDA in May 2017, it added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
